Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00244361
Other study ID # IND #11,771
Secondary ID SCRIHS (04-112)
Status Completed
Phase Phase 1/Phase 2
First received October 24, 2005
Last updated May 6, 2011
Start date June 2005
Est. completion date December 2007

Study information

Verified date May 2011
Source National Pediatric Myoclonus Center
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to reduce the symptoms of OMS by testing rituximab (Rituxan®), to remove B lymphocytes that make antibodies and trigger brain inflammation. Evidence suggests that autoimmune brain inflammation causes the symptoms of OMS. This study of blood and spinal fluid intends to find out what effect rituximab has on OMS and on the spinal fluid B-cells.

Rituximab targets and destroys B-cells, which make antibodies that can attack the brain and cause may OMS. It is infused through a vein over a period of several hours. Rituximab has been used widely and studied extensively since its approval in 1997 by the U.S. Food and Drug Administration (FDA) for non-Hodgkin's B-cell Lymphoma (NHL). Today, more than 300,000 patients have received rituximab, and it is part of more than 200 completed, ongoing, or planned clinical trials. Rituximab is not FDA-approved for OMS.


Description:

Opsoclonus-myoclonus syndrome (OMS) is a rare but pervasive, paraneoplastic neurological disorder, purported to be autoantibody-mediated. We demonstrated expansion of B-cells in cerebrospinal fluid (CSF) despite tumor resection, chemotherapy, or conventional immunotherapy. Whether B-cells can be purged from the CSF compartment with benefit to the patient is unknown. Targeting of CSF B lymphocytes represents a novel and valuable paradigm shift in the therapy of centrally-mediated paraneoplastic disorders. The objective of this preliminary study is to determine if rituximab, a monoclonal antibody against CD20+ B-cells, reduces or eliminates CSF B-cells in OMS and whether the reduction results in clinical improvement. B lymphocyte subsets and relevant T-cell subsets will be immunophenotyped in the CSF and peripheral blood of children with OMS by four-color dual-laser flow cytometry. Sixteen children with an increased percentage of CSF B-cells will be treated with rituximab 375 mg/m2 IV once weekly for four consecutive weeks and CSF testing will be repeated at six months with more frequent clinical evaluations and blood testing out to 12 months. Clinical outcome will be rated blindly from videotapes by an experienced observer using a validated 12-item motor evaluation scale and quantifiable parameters of sleep, behavior and motor function. Immunological outcome variables will include percentages of B-cell subsets and quantitative immunoglobulins. Post-treatment results will be compared to pre-treatment values statistically. If rituximab proves to be an efficacious and safe method of treating CSF B-cell expansion and the neurological syndrome, this study will lead to a phase II trial with the eventual aim of gaining FDA approval of rituximab for this indication.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date December 2007
Est. primary completion date December 2007
Accepts healthy volunteers No
Gender Both
Age group 6 Months to 19 Years
Eligibility Inclusion Criteria:

- written consent from parents

- have symptomatic OMS

- have CSF B-cell expansion (>1% B-cells)

- adequate renal function as indicated by normal BUN [10-25 mg/dL] and creatinine [0.4-1.2 mg/dL]

- adequate liver function, as indicated by up to 2x normal AST [0-35 U/L] and ALT [0-35 U/L].

- men and women of reproductive potential must agree to use an acceptable method of birth control during treatment and for twelve months after completion of treatment

Exclusion Criteria:

- treatment with any investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (which ever is longer)

- receipt of a live vaccine within 4 weeks prior to enrollment

- previous treatment with Rituximab

- prior antibody therapy (does not include IVIg) within past 6 months

- history of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies

- history of HIV (patients considered high risk will be screened)

- history of hepatitis B and/or hepatitis C (patients considered high risk will be screened)

- history of recurrent significant infection or history of recurrent bacterial infections

- known active bacterial, viral fungal mycobacterial, or other infection (including tuberculosis or atypical mycobacterial disease, but excluding fungal infections of nail beds) or any major episode of infection requiring hospitalization or treatment with i.v. antibiotics within 4 weeks of screening or oral antibiotics within 2 weeks prior to screening

- pregnancy (a negative serum pregnancy test should be performed for all women of childbearing potential within 7 days of treatment)

- significant cardiac (symptomatic arrhythmias or symptomatic structural heart disease) or pulmonary disease (including obstructive pulmonary disease)

- concomitant chemotherapy

- hemoglobin: >13.5 gm/dL or <10.0 gm/dL

- platelets: <100,000/mm or >500,000/mm K/cumm

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
rituximab


Locations

Country Name City State
United States National Pediatric Myoclonus Center, Department of Neurology, SIU School of Medicine, 751 N Rutledge St Springfield Illinois

Sponsors (2)

Lead Sponsor Collaborator
National Pediatric Myoclonus Center Genentech, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determine the effectiveness & selectivity of rituximab at depleting CSF B-cells in OMS with intrathecal B-cell expansion. This requires CSF & blood lympocyte immunophenotyping prior to the first infusion & intervals for 1 year after the final infusion.
Secondary Evaluate the clinical efficacy & safety of rituximab by clinical assessments, scoring of videotapes for neurological severity, and various blood tests prior to the first infusion and then at one, three, six, and twelve months post the final infusion.
See also
  Status Clinical Trial Phase
Completed NCT03722212 - Early Diagnosis of the GLUT1 Deficiency Syndrome With a Blood Based Test N/A
Completed NCT05563402 - "Evaluation of Usability and Safety of the Self-balancing Walking System Atalante in Patients With Multiple Sclerosis" N/A
Terminated NCT03645265 - Rhythmic Entrainment in Bilingual Speakers With Dysarthria N/A
Completed NCT05585541 - Teleassessment in Ataxic Multiple Sclerosis
Recruiting NCT05125666 - Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection Phase 2
Recruiting NCT03881930 - Balance Rehabilitation With Modified Visual Input in Patients With Neuropathy N/A
Completed NCT00950196 - Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia Phase 4
Completed NCT04183647 - Investigation of Acute Effects of Local Vibration and Whole-Body Vibration Applications N/A
Completed NCT03745248 - Aerobic Exercise, Balance Training, and Ataxia N/A
Completed NCT04099914 - Validation of a Clinical Algorithm for the Diagnosis of Recessive Ataxias
Recruiting NCT03945682 - The ASsessment and Physiotherapy managEment of Ataxia in Children Following Surgical Resection of Posterior Fossa Tumour N/A
Completed NCT01428544 - Special Drug Use Investigation (Retrospective) for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment (Over 100kg) N/A
Completed NCT00001324 - PET Scan to Study Brain Control of Human Movement
Recruiting NCT05486806 - Longitudinal Tracking of Patients Diagnosed With Neurodegenerative Movement Disorders
Completed NCT06001424 - Effect of Life Kinetik Training on Lower Limb Coordination in Ataxic Patients N/A
Completed NCT00692861 - Autoimmunity in Neurologic Complications of Celiac Disease
Recruiting NCT05885282 - Investigation of the Effects of Local Vibration Applied to Different Regions and Spinal Stabilization Exercises N/A
Recruiting NCT02841553 - Wolfram Syndrome and WFS1-related Disorders International Registry and Clinical Study
Not yet recruiting NCT06420271 - Effects of Cerebellar tACS-iTBS in Ataxia N/A
Completed NCT05621200 - Transcranial Alternating Current Stimulation (tACS) in Patients With Ataxia N/A